CompletedNot Applicable

Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent

Germany50 participantsStarted 2017-01-01

Plain-language summary

The purpose of this study is assessment of safety, efficacy, and short-term outcome of SQUID™ in the embolization of Dural Arteriovenous Fistula

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Dural Arteriovenous Fistula requiring endovascular treatment with a Lariboisiere score between 3 - 5 * Intended usage of SQUID™ * The patient agrees with the clinical data collection and medical file access. Exclusion Criteria: * DAVF with a Lariboisiere score \< 3 • Pregnancy

What they're measuring

Morbidity/Mortality

Timeframe: 90-180 days after treatment

Occlusion rate

Timeframe: 90 -180 days after treatment

Trial details

NCT IDNCT03524976

SponsorDr. Markus Alfred Möhlenbruch

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-07-30

View on ClinicalTrials.gov More Dural Arteriovenous Fistula trials